U.S. Wireless Telecom Stock News

NasdaqGM:TNDM
NasdaqGM:TNDMMedical Equipment

Tandem Diabetes Care Funding Move Tests Valuation And Acquisition Plans

Tandem Diabetes Care completed a private offering of convertible senior notes, paired with capped call transactions aimed at limiting future share dilution. The company indicated it may use a portion of the proceeds for general corporate purposes, including potential acquisitions. Tandem Diabetes Care, NasdaqGM:TNDM, is drawing attention as this capital move lands with the stock at $25.23. The share price is up 26.8% over the past month and 21.4% over the past year, even though the 3 year...
NasdaqGS:GFS
NasdaqGS:GFSSemiconductor

Is Shifting Short Interest Reframing GlobalFoundries’ (GFS) Risk Reward Profile in Semiconductor Foundries?

Recently, GLOBALFOUNDRIES Inc. reported that short interest as a share of its freely tradable float fell 6.2%, to 12.7%, still well above the 4.53% average for peers. This decline suggests a shift in sentiment even as the company remains one of the more heavily shorted names among comparable semiconductor foundries. We’ll now explore how this reduction in short interest fits into GlobalFoundries’ broader investment narrative and evolving risk-reward profile. The future of work is here...
NYSE:PEG
NYSE:PEGIntegrated Utilities

A Look At Public Service Enterprise Group (PEG) Valuation As Short Term Momentum Softens

Public Service Enterprise Group (PEG) has drawn fresh attention as investors reassess its recent share performance, with the stock showing mixed short term moves but positive returns over the past month and past 3 months. See our latest analysis for Public Service Enterprise Group. The recent pullback, including a 1 day share price return of 1.82% decline to US$84.50 and a softer 7 day share price return of 2.10% decline, comes after steadier gains. The 30 day and 90 day share price returns...
NasdaqGS:ZS
NasdaqGS:ZSSoftware

How Investors Are Reacting To Zscaler (ZS) Raising 2026 Guidance Despite a Wider Quarterly Loss

In late February 2026, Zscaler reported second-quarter results showing revenue rising to US$815.75 million while its net loss widened to US$34.31 million, and the company raised both third-quarter and full-year fiscal 2026 revenue and annual recurring revenue guidance. At the same time, Zscaler’s higher spending in a competitive market and concerns around billings, new customer growth, and integration of acquired businesses have led investors to question how durable its growth and path...
NasdaqCM:UFPT
NasdaqCM:UFPTMedical Equipment

UFP Technologies Deepens Intuitive Surgical Ties With Expanded Long Term Deal

UFP Technologies (NasdaqCM:UFPT) amended its manufacturing supply agreement with Intuitive Surgical. The amendment extends the term of the partnership between the two companies. Minimum volume commitments under the agreement were increased. A new program for additional products was added to the supply arrangement. For you as an investor, this centers on UFP Technologies' role as a specialized manufacturer for the medical device sector, supplying components and solutions to a leading global...
NYSE:MOD
NYSE:MODBuilding

Is Modine Manufacturing (MOD) Fairly Priced After Its Sharp Multi‑Year Share Price Surge

If you are wondering whether Modine Manufacturing's current share price actually lines up with its underlying worth, you are not alone. This article is going to focus squarely on what the numbers say about value. The stock last closed at US$238.50, with returns of 7.2% over 7 days, 29.2% over 30 days, 69.4% year to date and 209.2% over 1 year, while the 3 year return is very large and the 5 year return is around 15x. Recent news around Modine Manufacturing has largely centered on its role in...
NYSE:XPRO
NYSE:XPROEnergy Services

A Look At Expro Group Holdings (XPRO) Valuation After Earnings Guidance And New Buyback Program

Earnings, guidance and new buyback put Expro Group Holdings (XPRO) in focus Expro Group Holdings (XPRO) is back on investors’ radar after releasing fourth quarter and full year 2025 results, setting 2026 revenue guidance, and unveiling a new US$100 million share repurchase plan. The latest numbers give you a fresh look at how the business ended 2025. The guidance and buyback outline how management is thinking about the next phase. Here is what stands out from the announcement and how you...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Harrow’s PharmaPack Aims To Reshape Post Cataract Care And Cash Pay Use

Harrow (NasdaqGM:HROW) has introduced a new Direct-to-Prescriber PharmaPack offering focused on post-cataract surgery care. The PharmaPack kits provide access to FDA-approved ophthalmic products and are designed to be ordered directly by eye care providers. The launch aims to reduce reliance on off-label compounded formulations and support more standardized treatment protocols. For investors following ophthalmic therapeutics, Harrow sits at the intersection of branded eye care drugs and...
NYSE:OWL
NYSE:OWLCapital Markets

Blue Owl’s Liquidity Crackdown and ESOP Shelf Might Change The Case For Investing In OWL

In February 2026, Blue Owl Capital Inc. filed a US$615.5 million shelf registration for 50,000,000 Class A shares linked to an employee stock ownership plan, shortly after restricting withdrawals from a fund and planning to sell US$1.40 billion of assets across three funds to repay debt and return capital to investors. These moves, including the permanent removal of a quarterly withdrawal option in its smallest vehicle, highlight how Blue Owl is balancing growth ambitions with tighter...
NasdaqGS:SVRA
NasdaqGS:SVRABiotechs

Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application

Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and granted the therapy Priority Review, with a PDUFA action date set for August 22, 2026. The drug’s combination of Priority Review, Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations highlights both its potential clinical importance and the high...
NYSE:XYZ
NYSE:XYZDiversified Financial

Block Reshapes Workforce Around AI While Shares Trade Below Targets

Block (NYSE:XYZ) is cutting over 40% of its workforce as part of a major reorganization focused on artificial intelligence. CEO Jack Dorsey is repositioning the company around deep AI integration across products and operations. Management describes the move as proactive and from a position of financial strength, while also raising guidance. The restructuring is intended to streamline costs, speed up product development, and reshape Block’s business model. Block comes into this restructuring...
NYSE:TFC
NYSE:TFCBanks

Is Truist Financial (TFC) Pricing Reflect Its Recent Returns And Valuation Metrics

If you are wondering whether Truist Financial's current share price really lines up with its underlying worth, this article will walk through the key numbers that matter most. Over the short term, the stock has seen a 1.1% decline over 7 days and a 3.6% decline over 30 days. The longer term picture shows a 14.3% return over 1 year, 26.4% over 3 years, and 5.1% over 5 years from a last close of US$49.55. Recent market attention around large US banks has kept Truist Financial in focus,...
NYSE:XPEV
NYSE:XPEVAuto

Is XPeng (XPEV) Pricing In Too Much Hope After Prolonged Share Price Weakness

If you are wondering whether XPeng shares are pricing in too much hope or not enough, this article walks through what the current valuation really implies for investors. The stock recently closed at US$16.99, with returns of a 3.2% decline over 7 days, a 5.5% decline over 30 days, a 16.8% decline year to date, a 16.1% decline over 1 year and an 81.3% decline over 3 years, which gives a mixed picture of sentiment and risk. Recent headlines around XPeng have focused on broad themes such as...
NYSE:SM
NYSE:SMOil and Gas

SM Energy Refocuses Portfolio Toward Debt Reduction And Shareholder Returns

SM Energy (NYSE:SM) completed a US$950 million South Texas asset sale, aimed at reshaping its portfolio and paying down debt. The company announced a 10% increase in its quarterly dividend alongside a new US$500 million share repurchase program. These capital moves follow the recently completed merger with Civitas, signaling a sharper focus on shareholder returns. SM Energy, an independent oil and gas producer, is refocusing its portfolio at a time when many energy companies are rethinking...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Exact Sciences Holders Back Abbott Deal As Valuation Gap Draws Focus

Shareholders of Exact Sciences (NasdaqCM:EXAS) have approved the proposed acquisition by Abbott Laboratories. The vote clears a key step in the transaction process and moves the deal closer to completion. The approval reflects investor backing for the planned combination of the two healthcare companies. Exact Sciences focuses on cancer screening and diagnostic tests, an area that attracts attention as healthcare systems look for earlier detection and more personalized care. The approved...
NasdaqGS:VISN
NasdaqGS:VISNCommunications

Assessing Vistance Networks (VISN) Valuation After 2025 Results And Connectivity And Cable Solutions Sale

Vistance Networks (VISN) drew fresh attention after reporting 2025 results that included very large net income and a move from loss to profit, supported by the sale of its Connectivity and Cable Solutions segment. See our latest analysis for Vistance Networks. The share price reaction has been mixed, with a 1 day share price return of 1.59% after the results, a 90 day share price return showing an 8.51% decline, and a 1 year total shareholder return of very large magnitude that reflects how...
NasdaqGS:BKNG
NasdaqGS:BKNGHospitality

A Look At Booking Holdings (BKNG) Valuation After Mixed Short And Long Term Share Performance

Recent share performance and business snapshot Booking Holdings (BKNG) has drawn investor attention after a period of mixed share performance, with gains over the past week contrasting with weaker returns over the past month and over the past 3 months. The company, headquartered in Norwalk, Connecticut, runs platforms such as Booking.com, Priceline, Agoda, KAYAK and OpenTable, generating revenue of US$26.9b and net income of US$5.4b from global travel and restaurant reservation services. See...
NasdaqGS:PENN
NasdaqGS:PENNHospitality

Is PENN Entertainment (PENN) Now Attractively Priced After Recent Share Price Rebound?

This article examines whether PENN Entertainment at around US$14.85 appears attractively priced or potentially a value trap, by reviewing what the available numbers indicate about the stock. The share price has moved sharply in the short term, with a 22% return over the last 7 days and 15.7% over the last 30 days. This contrasts with a 28.5% decline over 1 year and a 51% decline over 3 years. Recent headlines have focused on PENN Entertainment's position in the US gaming and entertainment...
NYSE:MOS
NYSE:MOSChemicals

Mosaic (MOS) Valuation Check After Weak Earnings, Softer Phosphate Demand And Analyst Downgrades

Mosaic (MOS) is back in focus after its latest quarterly results showed a weak finish to 2025, with softness in U.S. phosphate demand, higher sulfur costs, and recent analyst downgrades pressuring sentiment. See our latest analysis for Mosaic. The earnings miss, analyst downgrades and softer U.S. phosphate demand have weighed on sentiment. The latest 1 day share price return of 1.19% and 7 day share price return of 4.25% contrast with a 90 day share price return of 12.84% and a 1 year total...
NasdaqCM:CMPX
NasdaqCM:CMPXBiotechs

How Palo Alto’s New Stake and Rising Institutional Ownership At Compass Therapeutics (CMPX) Has Changed Its Investment Story

Palo Alto Investors LP opened a new position in Compass Therapeutics in the fourth quarter of 2025, acquiring 2,532,419 shares valued at about US$13.6 million, or roughly 1.89% of its assets under management. This move, alongside expectations for Compass’s bispecific antibody Tovecimig (CTX-009) in biliary tract cancer, highlights growing institutional interest in its oncology pipeline. Next, we will examine how rising institutional ownership, anchored by Palo Alto Investors’ new stake,...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Why Viavi Solutions (VIAV) Is Up 29.2% After AI-Driven 6G RAN Digital Twin Breakthrough Simulation

NTT DOCOMO and Viavi Solutions recently completed a joint study using AI and digital twin technology to control 6G radio access networks, showing in simulations that cutting control overhead can lift system throughput by up to 20%, with results presented at Mobile World Congress Barcelona 2026. This work highlights Viavi’s growing role in AI-driven network optimization tools, positioning its test and simulation platforms at the center of future 6G architecture discussions. We’ll now examine...
NYSE:GVA
NYSE:GVAConstruction

Is It Too Late To Consider Granite Construction (GVA) After A 65% One Year Surge?

If you are wondering whether Granite Construction's share price still offers value after a strong run, or if most of the upside is already reflected, this article breaks down what the current market price might be implying. The stock most recently closed at US$133.84, with a 7 day return of a 0.7% decline, a 30 day return of 10.8%, a year to date return of 12.8%, a 1 year return of 65.3%, a 3 year return that is very large, and a 5 year return that is very large. Recent price moves sit...
NasdaqGS:SPSC
NasdaqGS:SPSCSoftware

Is SPS Commerce (SPSC) Now Attractive After A 55% One Year Share Price Slump

If you are wondering whether SPS Commerce shares are now priced attractively or still look expensive, you are not alone. This review is aimed squarely at that question. The stock most recently closed at US$58.41, with returns of 7.7% over the past week, a 34.6% decline over 30 days, a 33.6% decline year to date, and a 55.8% decline over 1 year. The 3 year and 5 year returns stand at 61.2% and 41.1% declines respectively. Recent coverage around SPS Commerce has focused on keeping investors...
NasdaqGM:VCYT
NasdaqGM:VCYTBiotechs

Veracyte (VCYT) Valuation Check After Mixed Short And Long Term Share Price Performance

Veracyte (VCYT) has drawn attention after recent share price moves, with the stock showing mixed returns across different time frames, including declines over the past month and past 3 months alongside a positive 1 year total return. See our latest analysis for Veracyte. At a share price of US$36.01, Veracyte’s recent performance reflects fading short term momentum, with a 30 day share price return of 5.44% and a 90 day share price return of a 21.99% decline, set against a 1 year total...